Improved agreement means NICE now recommends lung cancer treatment
Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published today by NICE.
Search results
294 results
-
-
Feeling safe and being heard in residential care is crucial
Dorothy Hodgkinson from Finding Perspectives discusses the importance of safeguarding adults in care homes
-
Be aware of the signs of abuse and neglect in adult care homes, says NICE
Staff and visitors can play a vital role in the identification and prevention of abuse and neglect in care homes for adults says NICE, in a draft guideline published today.
-
Nasal spray medicine for treatment-resistant depression not recommended by NICE
Consultation open on draft guidance until Friday 25 September 2020
-
Recruitment begins to fill up to seven non-executive roles on the NICE board
Roles will contribute to the development of NICE’s strategic objectives
-
New agreement means NICE recommends combination treatment for some lymphoma patients
Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE.
-
NICE extends consultation period for new quality standard on fetal alcohol spectrum disorder
NICE has today (20 August, 2020), released its draft quality standard on fetal alcohol spectrum disorder (FASD) for further public consultation.
-
NICE appoints two directors to key new positions
NICE has announced the appointment of two new directors to key positions in newly formed directorates.
-
Commonly used treatments for chronic pain can do more harm than good and should not be used, says NICE in draft guidance
A number of commonly used drug treatments for chronic primary pain have little or no evidence that they work and shouldn’t be prescribed, NICE has said in its draft clinical guideline published today (3 August 2020) on the assessment and management of chronic pain in over 16s.
-
New combination treatment for patients with advanced kidney cancer
Adults with advanced renal cell carcinoma can now be offered avelumab with axitinib as a first line treatment option on the Cancer Drugs Fund (CDF), NICE has said in final draft guidance.
-
NICE publishes new COVID-19 rapid guideline on arranging planned care in hospitals and diagnostic services
NICE has today (27 July 2020) published a guideline on the arrangements the NHS should put in place for patients needing elective surgery and other planned treatments and procedures (including diagnostics and imaging) during the COVID-19 pandemic.
-
NICE signs agreement with Colombia's Institute of Health Technology Assessment to forge closer working ties
Research and knowledge sharing key to collaborative working approach agreed the two agencies
-
NICE's strategy on sustainability: current progress and next steps
Fizzah Ali, NICE clinical fellow, outlines the key steps towards a sustainability strategy at NICE
-
Innovation through HTA: theme for HTAi 2021 Annual Meeting announced
Health Technology Assessment International (HTAi) has announced the theme for the 2021 Annual Meeting which will be held from 19-23 June in Manchester.
-
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
-
Cancer patients to benefit from new histology independent treatment
Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).
-
NICE begins phased restart of non-COVID-19 guidance
NICE has begun a phased restart of publishing non-COVID-19 guidance as the NHS and wider health and care system start to return to normal arrangements.
-
Steam treatment recommended for men with an enlarged prostate
Minimally invasive procedure involves injecting steam to destroy excess prostate tissue
-
NICE publishes latest COVID-19 guidance on renal transplantation
NICE has published new rapid COVID-19 guidance for children, young people and adults who need or who have had a kidney transplant, and people who are donating a kidney (live donors).
-
NICE recommends treatment for type of small-cell lung cancer
A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE.
-
NICE recommends 'game changing' histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
-
NICE chairman Sharmila Nebhrajani begins her new role
NICE is delighted to announce that today (26 May 2020) Sharmila Nebhrajani, OBE, has taken up her position as its new chairman following her appointment by the Secretary of State for Health and Social Care and an independent open recruitment process.
-
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body.
-
NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has today (15 May) published 2 new rapid COVID-19 guidelines. The first is on chronic kidney disease (CKD) and the second on interstitial lung disease.
-
NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
-
New COVID-19 guideline on acute kidney injury
NICE has published a new COVID-19 rapid guideline on acute kidney injury (AKI).
-
NICE publishes latest wave of COVID-19 guidelines
The first is on the care of children and young people who are immunocompromised and the second on antibiotics for pneumonia in adults in hospital.
-
NICE joins international collaboratives to respond to the COVID-19 pandemic
NICE is supporting a growing number of international collaborations to share knowledge and identify treatments in response to the COVID-19 pandemic.
-
NICE publishes two new COVID-19 guidelines
NICE has published 2 new rapid COVID-19 guidelines on the care of patients with suspected and confirmed COVID-19.
-
NICE publishes new COVID-19 guidelines on cystic fibrosis, chronic obstructive pulmonary disease (COPD) and dermatological conditions treated with drugs affecting the immune response
NICE has today (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.
-
NICE publishes new COVID-19 guidelines on severe asthma, pneumonia, rheumatological disorders and symptom management
They cover the management of patients with severe asthma, pneumonia, rheumatological autoimmune, inflammatory and metabolic bone disorders and the management of COVID-19 symptoms in the community.
-
NICE publishes second set of rapid COVID-19 guidelines
The new guidelines cover the provision of radiotherapy services and bone marrow transplant during the COVID-19 pandemic.
-
NICE updates rapid COVID-19 guideline on critical care
We have listened to concerns raised by patient groups about the application of our rapid COVID-19 critical care guideline.
-
NICE publishes first rapid COVID-19 guidelines
New guidelines cover the management of patients in critical care, the management of patients who are having kidney dialysis and the management of patients who are receiving systemic anticancer treatments.
-
NICE to produce rapid COVID-19 guidelines
NICE has today (20 March 2020) announced that it is developing a series of rapid guidelines with NHS England/Improvement on the active management of patients with suspected and confirmed COVID-19, and in patients without COVID-19, in a number of clinical areas.
-
NICE publishes its guideline on the diagnosis and management of abdominal aortic aneurysms
NICE has today (19 March 2020) published its guideline on the diagnosis and management of abdominal aortic aneurysms (AAA).
-
Professor Gillian Leng, CBE, appointed as new NICE Chief Executive
NICE has today (18 March 2020) announced that Professor Gillian Leng, CBE, has been appointed as its new Chief Executive.
-
“I don't want to talk about that right now.”
Hannah Everard from Thurrock Council discusses the importance of future planning
-
NICE publishes its first medtech briefing on artificial intelligence software
NICE publishes a Medtech Innovation Briefing on artificial intelligence for analysing CT brain scans
-
Around 10,000 people could benefit from new migraine drug as NICE says it's cost-effective
NICE has today (12 March 2020) published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva Pharmaceuticals) for preventing chronic migraine.
-
On World Kidney Day we find out what patients think of their kidney care
Fiona Loud from Kidney Care UK explains what PREM stands for and how it has impacted care in the UK
-
Helping patients to be heard: What the new NICE guidance means for people with tinnitus
Vai Maheswaran, Audiologist at Action on Hearing Loss UK
-
Strategic collaboration announced by NICE and Health Technology Wales
Collaboration outlines the strategic planning and delivery of independent and authoritative medical technology guidance
-
NICE recommends new 'chemotherapy-free' treatment for lymphoma
A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been approved by NICE.